10-Q · May 8, 2026
Tvardi Therapeutics reported a narrowed net loss of $6.8 million for Q1 2026 compared to $9.6 million in Q1 2025, improving EPS from -$3.72 to -$0.73. R&D expenses rose significantly, driven mainly by the development of…
Earnings analysis · 10-Q
TVRD earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
Tvardi reported diluted EPS of $(0.69) and a $6.5 million net loss, with no revenue, margin, segment, or free-cash-flow data disclosed in the available filing text. Liquidity of $15.8 million was expected to fund…
Read full summary
Tvardi reported diluted EPS of $(0.69) and a $6.5 million net loss, with no revenue, margin, segment, or free-cash-flow data disclosed in the available filing text. Liquidity of $15.8 million was expected to fund planned operations through the HCC topline readout in Q3 2027, but UC trial initiation in 2027 depends on IND clearance and additional funding. Sentiment is neutral because the stated cash runway and remediation efforts are offset by continuing losses, unresolved material weaknesses, and litigation and financing risks.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.69
What stood out
-
Quarterly loss remains significant
Reported diluted EPS was $(0.69) and net loss was $6.5 million for the quarter; revenue and free cash flow were not disclosed in the available filing text.
-
Cash runway extends to Q3 2027
Management stated that $15.8 million of cash, cash equivalents and short-term investments was expected to fund currently planned operations through the HCC topline readout in Q3 2027.
-
Material weakness remediation underway
The company stated that it has begun a formal risk-assessment process, established a monitoring program, and added experienced accounting and financial-reporting personnel to address the identified control deficiencies.
-
No new market-risk exposure reported
The company reported no material changes to its quantitative and qualitative market-risk disclosures from the Form 10-K filed on March 31, 2026.
What to watch
-
Material weaknesses remain unresolved
As of June 30, 2026, management concluded that disclosure controls and procedures were not effective because of material weaknesses in internal control over financial reporting, including inadequate review of financial statements and CRO-related prepaid and accrued R&D expenses.
-
Registration-rights litigation
A complaint filed on March 6, 2026 alleges breach of the Registration Rights Agreement for failure to timely cause a resale registration statement to become effective. Although a majority of holders waived the right, litigation could still generate defense costs and divert management resources.
-
Additional funding and regulatory risk
The company stated that initiating TTI-109 trials in UC in 2027 is subject to IND clearance and additional funding, while the reported $15.8 million liquidity is expected to support currently planned operations only through the HCC topline readout in Q3 2027.
Management's outlook
No quantitative revenue or EPS guidance was provided in the 10-Q. Management previously stated that cash, cash equivalents and short-term investments of $15.8 million were expected to fund currently planned operations through the HCC topline readout in Q3 2027; initiating TTI-109 trials in UC in 2027 remains subject to IND clearance and additional funding.
Earlier filings 4
10-K · March 31, 2026
Tvardi positions itself as a clinical‑stage, STAT3‑focused small‑molecule biopharma advancing two oral candidates (TTI‑101 and TTI‑109). The filing discloses upcoming clinical catalysts (TTI‑109 Phase 1 topline in Q2…
10-Q · November 13, 2025
Tvardi reported no product revenue and a Q3 2025 net loss of $5.5M (basic and diluted loss per share of $0.59), an improved loss per share versus Q3 2024 of $2.14. R&D spending declined while G&A rose after the April…
10-Q · August 14, 2025
Tvardi reported GAAP net income of $4,167 thousand for Q2 2025 (three months ended June 30, 2025) driven primarily by a $12.8 million fair-value remeasurement benefit, while core operations produced a loss from…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.